Armaviscon Plus 1.5% syringe 2 ml, 2 pcs.

The field of application is orthopedics, rheumatology, traumatology, surgery, sports medicine.

The product Armaviscon Plus is a protector of synovial joint fluid. It is used against the background of degenerative changes of the synovial cartilage surface to improve joint mobility, decrease pain syndrome, decrease inflammatory reactions and restore homeostasis in the cartilage.

Properties and efficacy:

The product has an analgesic, corrective effect on the metabolism of bone and cartilage.

Harmaviscon Plus is a sterile, highly purified, highly molecular solution of sodium salt of hyaluronic acid (sodium hyaluronate).

Hyaluronic acid is an essential component of the extracellular matrix and is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity of synovial fluid, and it is also necessary for the formation of cartilage. In osteoarthritis there are deficiencies and qualitative changes in hyaluronic acid in the synovial fluid and cartilage. Intra-articular injection of hyaluronic acid leads to improvement of the functional state of the joint.

When using Armaviscon Plus in osteoarthritis of the knee joint improvement of the clinical course of osteoarthritis is observed up to six months after application, an anti-inflammatory and analgesic effect is observed due to restoring the volume and viscosity and elasticity of synovial fluid that fills the joint cavity and acts as an intraarticular lubricant. It prevents friction of the articular surfaces, which eliminates pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, provides mobility, and has cushioning abilities (absorbs external shock, protecting the components of the joint from damage).

The solution of sodium hyaluronate is distributed locally in the joint cavity, where it undergoes local transformations with a lubricating effect. Extracting or replacing the product is not applicable as it is inseparably mixed with the synovial fluid of the joint.

Indications

To increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints;
For rehabilitation after arthroscopy;
For the treatment of patients who have increased physical activity and regularly load the affected joint.

Pharmacological effect

Area of ​​application: orthopedics, rheumatology, traumatology, surgery, sports medicine.

Armaviscon Plus is a protector of joint synovial fluid. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore homeostasis in the cartilage.

Properties and effectiveness:

The drug has an analgesic and corrective effect on the metabolism of bone and cartilage tissue.

Armaviscon Plus is a sterile viscous solution of the sodium salt of hyaluronic acid (sodium hyaluronate) of high purity, high molecular weight.

Hyaluronic acid is an essential component of the extracellular matrix and is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity to synovial fluid, and is also necessary for the formation of cartilage. With osteoarthritis, there is a deficiency and qualitative changes in hyaluronic acid in the composition of synovial fluid and cartilage. Intra-articular injection of hyaluronic acid leads to an improvement in the functional state of the joint.

When using Armaviscon Plus for osteoarthritis of the knee joint, there is an improvement in the clinical course of osteoarthritis up to six months from the date of use, an anti-inflammatory and analgesic effect is observed due to replenishment of the volume and restoration of the viscosity and elasticity of the synovial fluid, which fills the joint cavity and acts as an intra-articular lubricant. It prevents friction of the articular surfaces, which eliminates pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, ensures mobility, and has shock-absorbing capabilities (dampens external shocks, protecting joint components from damage).

The sodium hyaluronate solution is distributed locally into the joint cavity, where it undergoes local transformations, providing a lubricating effect. Removing or replacing the product is not applicable, since it is inseparably mixed with the synovial fluid of the joint.

Special instructions

Do not use Armaviscon Plus with damaged or opened packaging.

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and is carefully purified. However, the physician must consider the potential risks associated with injecting any biological substance.

Extra-articular administration of Armaviscon Plus into the joint capsule or synovial tissue is not allowed. This may cause local side effects.

It is unacceptable for the product to enter blood vessels. During the first 2 days after the procedure, it is recommended not to overload the joint, especially prolonged loading should be avoided.

Armaviscon Plus does not affect a person’s ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Patients with inflammatory diseases, in particular with ankylosing spondylitis and rheumatoid arthritis, are not prescribed Armaviscon Plus.

Not intended for children.

For single use only.

Follow national and local rules and regulations to ensure safe use and disposal of used needles.

Requirements for the use and operation of a medical device:

The product refers to products for individual and single use.

Carrying out procedures with this medical device requires special training and special skills and is intended for use in medical institutions.

Composition

Composition per 1 ml:

sodium hyaluronate – 13.5-16.5 mg/ml (1.5%),

sodium chloride – 8.50 mg/ml,

sodium hydrogen phosphate dihydrate – 0.22 mg/ml,

sodium dihydrogen phosphate dihydrate – 0.044 mg/ml,

water for injection – up to 1 ml.

Contraindications

Use during pregnancy and breastfeeding:

It is not recommended to use the product during pregnancy and breastfeeding due to the lack of clinical data. Prescription of the drug during pregnancy and breastfeeding is at the discretion of the orthopedic surgeon. Contraindications for use:

hypersensitivity to the components of the product;

the presence of infection or damage to the skin in the injection area;

acute synovitis;

children under 18 years of age (due to lack of clinical data).

Side Effects

Moderate pain, swelling, increased temperature and redness in the injection area, and an increase in exudate in the joint cavity may occur.

The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to unload the affected joint and apply ice. Allergic reactions can occur extremely rarely.

Interaction

Armaviscon Plus should not be prescribed simultaneously with other intra-articular injections due to the lack of significant experience.

Disinfectants containing quaternary ammonium compounds should not be used, since hyaluronic acid precipitates in the presence of these substances.

Storage conditions

Store at temperatures from + 2 °C to + 25 °C. Do not freeze.

Manufacturer

Grotex LLC, Russia